FMI expects the fibrin glue market to grow from USD 48.7 billion in 2026 to USD 76.9 billion by 2036, rising at a 5.2% CAGR. Recombinant production holds 55% share in 2026, driven by safety advantages over plasma-derived alternatives, while hemostats account for 60% of the market by type.